Skip to main content
Premium Trial:

Request an Annual Quote

NanoInk Begins Offering Dried Blood Spot Analysis for Protein Biomarker Research

Premium

Nanotechnology firm NanoInk said this week that it has begun offering dried blood spot analysis for protein biomarker research on a contract services basis.

The company will use its NanoArray Assay System for the detection, identification, and quantification of clinically relevant protein biomarkers from samples collected on dried blood spots via finger-stick blood draws.

DBS samples are minimally invasive, low-cost, and require little equipment to obtain, but because they contain only a small amount of sample, they are often unsuitable for analysis of low-abundance proteins via conventional immunoassays like ELISAs.

According to NanoInk, the NanoArray Assay System is capable of working with sample volumes as low as 2 µL and can detect proteins in the sub-picogram per mL range, making it well-suited to DBS analysis.

In a recently completed study, the platform demonstrated the ability to detect four clinically relevant cytokines – IL-1β, IL-4, IL-6, and TNF-α – at the single picogram per mL level in sample volumes between 4 and 5 µL, the company said.

The NanoArray Assay System is based on the company's dip pen nanolithography-fabrication technique, which uses sharp probes to spot biomolecules onto a surface.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.